强脉冲光治疗睑板腺功能障碍性干眼的疗效分析

注册号:

Registration number:

ChiCTR2400083355 

最近更新日期:

Date of Last Refreshed on:

2024-04-22 16:30:36 

注册时间:

Date of Registration:

2024-04-22 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

强脉冲光治疗睑板腺功能障碍性干眼的疗效分析

Public title:

Analysis of the efficacy of intense pulsed light in the treatment of meibomian gland dysfunction dry eye

注册题目简写:

English Acronym:

研究课题的正式科学名称:

强脉冲光治疗睑板腺功能障碍性干眼的疗效分析

Scientific title:

Analysis of the efficacy of intense pulsed light in the treatment of meibomian gland dysfunction dry eye

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

周嘉楠 

研究负责人:

周嘉楠 

Applicant:

Jianan Zhou 

Study leader:

Jianan Zhou 

申请注册联系人电话:

Applicant telephone:

+86 18367815391

研究负责人电话:

Study leader's
telephone:

+86 18367815391

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

308991056@qq.com

研究负责人电子邮件:

Study leader's E-mail:

308991056@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省海宁市钱江东路2号

研究负责人通讯地址:

浙江省海宁市钱江西路2号海宁市人民医院

Applicant address:

No. 2 Qianjiang East Road, Haining City, Zhejiang Province

Study leader's address:

haining qianjiangxilu 2 hao

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

海宁市人民医院

Applicant's institution:

Haining People's Hospital

研究负责人所在单位:

海宁市人民医院

Affiliation of the Leader:

haining people hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024伦审030号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

海宁市人民医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Haining People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-01-25 00:00:00

伦理委员会联系人:

沈琴

Contact Name of the ethic committee:

Shen Qin

伦理委员会联系地址:

浙江省海宁市钱江西路2号海宁市人民医院

Contact Address of the ethic committee:

haining qianjiangxilu 2 hao

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 573 89230032

伦理委员会联系人邮箱:

Contact email of the ethic committee:

303242431@qq.com

研究实施负责(组长)单位:

海宁市人民医院

Primary sponsor:

haining people hospital

研究实施负责(组长)单位地址:

浙江省海宁市钱江西路2号海宁市人民医院

Primary sponsor's address:

haining qianjiangxilu 2 hao

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江

市(区县):

Country:

China

Province:

Zhejiang

City:

单位(医院):

海宁市人民医院

具体地址:

浙江省海宁市钱江西路2号海宁市人民医院

Institution
hospital:

haining people hospital

Address:

haining qianjiangxilu 2 hao

经费或物资来源:

海宁市2023年科技计划项目

Source(s) of funding:

Haining Science and Technology Plan Project in 2023

研究疾病:

干眼  

Target disease:

Dry eye

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

分析、总结强脉冲光治疗干眼的机制,比较其与传统雾化熏蒸治疗干眼之间的优劣势,产出相应的研究论文。  

Objectives of Study:

Analyze and summarize the mechanism of intense pulsed light therapy for dry eyes, compare its advantages and disadvantages with traditional nebulization fumigation therapy for dry eyes, and produce a paper.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.妊娠和哺乳期妇女。;
2.有角膜炎症或严重眼病。;
3.有严重心脑血管等全身疾病。;
4.有精神疾病者。;

Exclusion criteria:

1.Pregnant and lactating women.;
2.Keratitis or severe eye disease.;
3.Severe systemic diseases such as cardiovascular and cerebrovascular diseases.;
4.Individuals with mental illness.;

研究实施时间:

Study execute time:

From 2023-12-01 00:00:00 To 2025-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-01-27 00:00:00 To 2024-12-31 00:00:00

干预措施:

Interventions:

组别:

强脉冲光治疗组

样本量:

50

Group:

Intense Pulsed Light therapy group

Sample size:

干预措施:

强脉冲光

干预措施代码:

Intervention:

Intense Pulsed Light

Intervention code:

组别:

雾化熏蒸治疗组

样本量:

50

Group:

Atomization fumigation therapy group

Sample size:

干预措施:

雾化熏蒸

干预措施代码:

Intervention:

Atomization fumigation

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

海宁市人民医院 

单位级别:

三级乙等 

Institution
hospital:

haining people hospital

Level of the institution:

Tertiary B

测量指标:

Outcomes:

指标中文名:

泪膜破裂时间

指标类型:

主要指标

Outcome:

Tear film rupture time

Type:

Primary indicator

测量时间点:

治疗后1周、1和3个月

测量方法:

干眼分析仪

Measure time point of outcome:

1 week, 1 and 3 months after treatment

Measure method:

Dry eye analyzer

指标中文名:

泪河高度

指标类型:

主要指标

Outcome:

tear stream height

Type:

Primary indicator

测量时间点:

治疗后1周、1和3个月

测量方法:

干眼分析仪

Measure time point of outcome:

1 week, 1 and 3 months after treatment

Measure method:

Dry eye analyzer

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

研究公开发表后半年上传到临床试验公共管理平台ResMan (www.medresman.org.cn)。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The research will be uploaded to the clinical trial public management platform ResMan (www.medrescman. org. cn) six months after its public publication.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

case record form

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2024-04-22 16:29:50